Abstract：
Background: Adjuvant chemotherapy (AC) regimens tegafur/gimeracil/oteracil (S-1) and capecitabine plus oxaliplatin (CAPOX) have predominated, however, there has been a lack of studies on their differences in efficacy. Methods: We conducted pairwise meta-analyses comparing the efficacy of S-1 and CAPOX regimens for overall survival (OS) and disease-free survival (DFS) in stage II or III GC patients. Results: Three studies were enrolled and analyzed using a forest plot for meta-analysis. Two of them were propensity score matching studies, and the remaining one was a retrospective observational study. In all stages, the five-year OS was not different between the two regimens (HR 0.96, 95% CI 0.78-1.17; p = 0.56). Additionally, the 5-year DFS was not different at any stage (HR 1.00, 95% CI 0.85-1.18; p = 0.21). After omitting the retrospective observational study, the five-year OS (HR 1.40, 95% CI 0.53-3.73) and DFS (HR 1.41, 95% CI 0.57-3.44) of S-1 tended to be better in stage II, and the five-year OS (HR 0.81, 95% CI 0.56-1.16) and DFS (HR 0.85, 95% CI 0.63-1.13) of CAPOX tended to be better in stage III, without statistical significance. Conclusions: In the present meta-analysis, the five-year OS and DFS for stage II or III GC patients were comparable between S-1 and CAPOX regimens as AC.
摘要：
背景：辅助化疗（AC）方案替加氟/吉马拉西/奥瑟拉西（S-1）和卡培他滨联合奥沙利铂（CAPOX）占主导地位，然而,一直缺乏关于它们疗效差异的研究.方法：我们进行了配对荟萃分析，比较了S-1和CAPOX方案对II期或III期GC患者的总生存期（OS）和无病生存期（DFS）的疗效。结果：纳入了三项研究，并使用森林地块进行了荟萃分析。其中两项是倾向得分匹配研究，其余一项为回顾性观察性研究.在所有阶段,两种方案的5年OS无差异(HR0.96,95%CI0.78~1.17;p=0.56).此外,5年DFS在任何阶段均无差异(HR1.00,95%CI0.85-1.18;p=0.21).在省略回顾性观察研究后，S-1的五年OS（HR1.40，95％CI0.53-3.73）和DFS（HR1.41，95％CI0.57-3.44）在第二阶段趋于更好，CAPOX的五年OS（HR0.81，95%CI0.56-1.16）和DFS（HR0.85，95%CI0.63-1.13）在第三阶段趋于更好，没有统计学意义。结论：在本荟萃分析中，在S-1和CAPOX方案中,II期或III期GC患者的5年OS和DFS与AC具有可比性.
